1. Home
  2. Directory
  3. New York
  4. New York New York
  5. Psychiatry Neurology
  6. NPI Profile
  7. Prescriptions 1740741321

PRIYANKA MOONDRA DO
Prescription History 1740741321
Psychiatry & Neurology - Neurology in New York, NY

NPI Status: Active since March 27, 2019

Contact Information

135 E 37TH ST
NEW YORK, NY
ZIP 10016
Phone: (212) 434-6400

Get Directions

Prescription History for Informed Healthcare Decisions

Explore the verified Medicare Part D prescription history, volume metrics, and calculated drug costs for PRIYANKA MOONDRA DO, an active Neurology specialist practicing in New York, NY. Our medical registry currently tracks 3 unique pharmaceutical formulations prescribed by this provider, representing an estimated volume of 77 documented patient claims. Among these therapy options, the most frequently utilized medication is Carbidopa-Levodopa, which accounts for 49 claims alone.

Medication Index

C
P
No matching medications currently found on file.

Carbidopa-Levodopa

Generic Formulation: Carbidopa/LevodopaSpecialty: Student in an Organized Health Care Education/Training Program
Provider Metrics Summary
Total Claims 49
30-Day Fills 82.3
Days Supply 2,458
NY State Average Benchmarks
Peer Average Claims62.0
Peer Average 30-Day Fills101.2
Peer Average Days Supply2,874
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across NY. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $1,964.08 across this reporting matrix range.

Provider Avg Cost Per Claim

$40.08

State Avg Cost Per Claim

$42.15

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This combination medication is used to treat symptoms of Parkinson's disease or Parkinson-like symptoms (such as shakiness, stiffness, difficulty moving). Parkinson's disease is thought to be caused by too little of a naturally occurring substance (dopamine) in the brain. Levodopa changes into dopamine in the brain, helping to control movement. Carbidopa prevents the breakdown of levodopa in the bloodstream so more levodopa can enter the brain. Carbidopa can also reduce some of levodopa's side effects such as nausea and vomiting.

Carbidopa-Levodopa Er

Generic Formulation: Carbidopa/LevodopaSpecialty: Student in an Organized Health Care Education/Training Program
Provider Metrics Summary
Total Claims 16
30-Day Fills 38.0
Days Supply 1,140
NY State Average Benchmarks
Peer Average Claims42.0
Peer Average 30-Day Fills75.4
Peer Average Days Supply2,177
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 61.9% less volume than the regional standard for practitioners inside NY. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $710.63 across this reporting matrix range.

Provider Avg Cost Per Claim

$44.41

State Avg Cost Per Claim

$67.87

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This combination medication is used to treat symptoms of Parkinson's disease or Parkinson-like symptoms (such as shakiness, stiffness, difficulty moving). Parkinson's disease is thought to be caused by too little of a naturally occurring substance (dopamine) in the brain. Levodopa changes into dopamine in the brain, helping to control movement. Carbidopa prevents the breakdown of levodopa in the bloodstream so more levodopa can enter the brain. Carbidopa can also reduce some of levodopa's side effects such as nausea and vomiting.

Primidone

Generic Formulation: PrimidoneSpecialty: Student in an Organized Health Care Education/Training Program
Provider Metrics Summary
Total Claims 12
30-Day Fills 18.5
Days Supply 525
NY State Average Benchmarks
Peer Average Claims33.0
Peer Average 30-Day Fills51.8
Peer Average Days Supply1,510
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 63.6% less volume than the regional standard for practitioners inside NY. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $132.65 across this reporting matrix range.

Provider Avg Cost Per Claim

$11.05

State Avg Cost Per Claim

$25.02

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A barbiturate derivative that acts as a GABA modulator and anti-epileptic agent. It is partly metabolized to PHENOBARBITAL in the body and owes some of its actions to this metabolite.

Therapeutic Applications

This medication is used alone or with other medications to control seizures. Controlling and reducing seizures lets you do more of your normal daily activities, reduces your risk of harm when you lose consciousness, and lessens your risk for a possibly life-threatening condition of frequent, repeated seizures. Primidone belongs to a class of drugs known as barbiturate anticonvulsants. It works by controlling the abnormal electrical activity in the brain that occurs during a seizure.

Dataset Methodology & CMS Source Information

This analytical profile maps public infrastructure records sourced directly from official **Centers for Medicare & Medicaid Services (CMS)** public data releases. The statistics above track documented pharmaceutical treatment trends assigned to beneficiaries specifically under federal public programs. Evaluating the prescriptive footprints of clinical practitioners like PRIYANKA MOONDRA DO provides transparency into local medical care patterns within New York, NY.

Key Learning Objectives for this Profile:

  • Prescribing Frequencies: Track and evaluate the volume metrics of specific brand-name and generic medical formulas chosen by this provider over time.
  • Clinical Focus Areas: Identify how the provider distributes therapeutic selections across medical care options to gain insight into their true day-to-day **Neurology** practice concentrations.
  • Program Cost Awareness: Review the calculated total systemic drug costs and raw transactional volumes linked to these orders to better anticipate network insurance coverage structures.
  • Patient-Centered Evaluation: Cross-reference localized regional care comparisons to align practitioner habits directly with your proactive health maintenance goals.

Data Scope Exclusion & Limitations: The data elements presented above explicitly reflect prescription orders processed for Medicare beneficiaries during the year 2023. This informational profile does not aggregate prescription data for individuals utilizing private commercial health plans, state Medicaid coverage, or self-pay options. However, because medical decision-making remains highly consistent across clinical settings, this public registry provides a reliable proxy for understanding the general prescribing preferences and pharmaceutical care approach used by this provider.